

an Open Access Journal by MDPI

# Demyelinating Diseases and How They Affect the Central and Peripheral Nervous System - Molecular Disease Mechanisms, Neuropathology, Treatment and Rehabilitation

Guest Editor:

### Dr. Manuel Zeitelhofer

Karolinska Institutet, Stockholm, Sweden

Deadline for manuscript submissions:

closed (31 May 2023)

## **Message from the Guest Editor**

Demyelinating diseases are commonly associated with a significant reduction of quality of life, in addition to long-term sick leaves. Thus, this disease group—including conditions such as multiple sclerosis, Guillain–Barré syndrome, peripheral neuropathies, leukoencephalopathies, myelitis and neuromyelitis optica—represents a major social and economic burden. In addition, the COVID-19 pandemic has rendered this patient group more vulnerable and has limited the possibilities for in-house rehabilitation.

Hence, it is paramount to increase our understanding of the underlying disease and pathological mechanisms. Equally important is to foster the translational aspect, so that findings from the basic research can be correlated to the clinic

This Special Issue invites original articles, reviews, case reports, communications and opinions about underlying disease mechanisms, as well as the neuropathology, treatment and rehabilitation of demyelinating diseases, with the aim of improving our overall understanding of these diseases and the outcome of patient care, respectively.













an Open Access Journal by MDPI

## **Editor-in-Chief**

Prof. Dr. Stephen D. Meriney Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA

## **Message from the Editor-in-Chief**

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, CAPlus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.9 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

#### **Contact Us**